Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Indivior loses U.S. district court battle, copycat launches imminent

Written by: | no-reply@reuters.com | Dated: Tuesday, February 12th, 2019

 

(Reuters) – Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch sales next week after the firm’s attempt to stay a U.S. District court judgement was rejected.

The company said on Tuesday it would file a repeat motion to the Supreme Court, after having said last week that it faces rapid losses in market share “in the immediate future” to generic versions of Suboxone.

Earlier this month, a mandate by the U.S. Court of Appeals for the Federal Circuit opened the gates to rivals including India’s Dr. Reddy’s.

 

Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur

 

Reuters source:

https://www.reuters.com/article/us-indivior-suboxone/indivior-loses-u-s-district-court-battle-copycat-launches-imminent-idUSKCN1Q10P6

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom